Environmental exposures are likely to be a significant factor in the etiology of several diseases including neurodegenerative disease ([@b20-ehp0115s1-000129]), coronary heart disease ([@b47-ehp0115s1-000129]), cancer ([@b13-ehp0115s1-000129]; [@b33-ehp0115s1-000129]), and diabetes ([@b3-ehp0115s1-000129]). Epidemiologic studies examining demographic differences in disease incidence and altered risk patterns among migrant populations ([@b31-ehp0115s1-000129]) lends weight to the notion that xenobiotics play an important role in disease causation ([@b37-ehp0115s1-000129]). Humans are variously and continuously exposed to mixtures of disease-implicated xenobiotics via environment and/or diet ([@b19-ehp0115s1-000129]). Toxicity testing employing high-dose treatments with individual agents may be an inappropriate means of assessing low-dose exposures ([@b45-ehp0115s1-000129]). Different damage-induction mechanisms at low-dose versus high-dose concentrations may occur ([@b16-ehp0115s1-000129]; [@b18-ehp0115s1-000129]). Following exposures to mixtures, additive, synergistic, inhibitory and/or stimulatory interactions between different xenobiotics may occur.

Candidate and ubiquitous xenobiotics include polycyclic aromatic hydrocarbons (PAHs) {e.g., benzo\[*a*\]pyrene (B\[*a*\]P)}, heterocyclic aromatic amines {e.g., 2-amino-1-methyl-6-phenylimidazo\[4,5-*b*\]pyridine (PhIP)} and persistent organic pollutants (POPs) \[e.g., lindane; γ-hexachlorocyclohexane (γ-HCH)\] ([@b18-ehp0115s1-000129]). B\[*a*\]P is a procarcinogen that requires metabolic activation to 7,8-diol 9,10-oxides ([@b39-ehp0115s1-000129]); these ultimate carcinogenic and electrophilic species bind covalently with the N2 position of guanine ([@b2-ehp0115s1-000129]; [@b36-ehp0115s1-000129]). PhIP is a protein-derived mutagen that appears to possess significant estrogenic properties ([@b10-ehp0115s1-000129]; [@b12-ehp0115s1-000129]; [@b22-ehp0115s1-000129]). It is metabolically activated via a two-step mechanism initially involving conversion to *N*-hydroxy-PhIP ([@b5-ehp0115s1-000129]; [@b48-ehp0115s1-000129]) followed by esterification to a metabolite that binds to the C8 position of guanine ([@b38-ehp0115s1-000129]). Lindane is a lipophilic pesticide that moves through environmental compartments ([@b26-ehp0115s1-000129]) and may induce genomic alterations in the form of micronuclei ([@b18-ehp0115s1-000129]).

Biotransformation is often facilitated by oxidative metabolism via the cytochrome P450 (CYP) mixed-function oxidase system. The CYP multigene family consists of constitutively-expressed, inducible isoenzymes that are found mainly in the liver but also to varying degrees in extrahepatic sites ([@b34-ehp0115s1-000129]). The proteins of the B-cell leukemia/lymphoma-2 (Bcl-2) family regulate the permeability of the outer mitochondrial membrane ([@b42-ehp0115s1-000129]) and apoptosis ([@b1-ehp0115s1-000129]), and also appear to be modulators of oncogenic progression ([@b41-ehp0115s1-000129]). Through a modulation of Bcl-2:Bcl-2-associated X (Bax), PhIP appears to delay the involution of the rat mammary gland ([@b43-ehp0115s1-000129]); dysregulation effects that may not be dissimilar to those induced by 17β-estradiol (E~2~) ([@b23-ehp0115s1-000129]).

In previous studies, we demonstrated the genotoxicity of nanomolar concentrations of endogenous estrogens (E~2~, estrone, or estriol) ([@b46-ehp0115s1-000129]) and low-dose lindane ([@b18-ehp0115s1-000129]). Subsequently, it was shown that endogenous oestrogens or human milk-fat extracts, known to contain organo-chlorinated and brominated xenobiotics, markedly enhanced B\[*a*\]P-induced genotoxicity in clonogenic MCF-7 cells ([@b7-ehp0115s1-000129]; [@b17-ehp0115s1-000129]). Such exposures were associated with an elevation in the ratio of the anti-apoptotic Bcl-2 to the pro-apoptotic Bax proteins ([@b18-ehp0115s1-000129]). If low-dose treatments (for the experiments described herein, less than or equal to nanomolar concentrations of test agent in culture medium) induce genotoxic and/or intracellular modulations, then quantifying and modeling co-exposure effects at such environmentally relevant levels are of utmost importance. In this study we examined the effects of various binary mixtures consisting of a DNA-reactive procarcinogen (B\[*a*\]P or PhIP) and hormone-like agent (E~2~ or lindane) to determine whether such *in vitro* exposures might markedly modulate genotoxicity and/or survival in damaged cells. Our goal was to determine whether low-dose exposure to such a binary mixture might give rise to a modulation both of genotoxicity and survival in target cells.

Materials and Methods
=====================

Chemicals and media
-------------------

Unless otherwise stated, chemicals were obtained from Sigma Chemical Co. (Poole, UK), cell culture consumables from Invitrogen Life Technologies (Paisley, UK), and antibodies from Dako Cytomation (Ely, UK).

Cell culture
------------

The estrogen-responsive breast carcinoma MCF-7 cell line was grown in Dulbecco's modified essential medium supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL penicillin and 100 μg/mL streptomycin. MCF-7 cells were cultured routinely in 75-cm^2^ flasks at 5% CO~2~ in air and 37°C in a humidified atmosphere and subcultured (1:10, vol/vol) twice weekly. Before subculture or incorporation into experiments, cultured cells were disaggregated, with 0.05% trypsin/0.02% EDTA.

The cytokinesis-block micronucleus (CBMN) assay
-----------------------------------------------

MCF-7 cells were treated with B\[*a*\]P, PhIP, E~2~, or lindane either individually or as a binary mixture, as indicated. Additions of test agent(s), in dimethylsulfoxide (DMSO), were made to a maximum concentration of 1% vol/vol.

After disaggregation and resuspension in complete medium, MCF-7 cells in 3-mL aliquots (≈ 1 × 10^4^ cells) were seeded into 30-mm petri dishes containing 20-mm diameter coverslips (Sarstedt, UK). Cells were allowed to attach for 24 hr before the addition of test agent(s). After 24-hr treatment, the medium was replaced with fresh medium containing 2 μg/mL cytochalasin-B. Cultured for a further 24 hr, cells were fixed with 70% ethanol (EtOH) after washing the coverslips with phosphate-buffered saline (PBS). Cells were then stained with 5% Giemsa (in dH~2~O) before mounting the coverslips in DPX mountant (BDH Laboratory Supplies, Poole, UK) on microscope slides ([@b46-ehp0115s1-000129]).

For each treatment condition, micronuclei (MNi) in 1,000 binucleate MCF-7 cells from a minimum of three experiments were objectively scored either as micronucleated binucleate cells (MN), as the total number of micronuclei (TMN) or as the distribution of MNi in binucleate cells. Mitotic rate was assessed as percentage of binucleate cells (mean ± SD, *n* = 3 counts of 500 cells). In 10 separate experiments, in the population of MCF-7 cells used in this study, ≤ 5% fluctuation in the micronucleus-forming activity of 10^−6^ M B\[*a*\]P was observed.

The clonogenic assay
--------------------

MCF-7 cells were disaggregated and resuspended in complete medium. Aliquots (5 mL) containing ∼ 1 × 10^3^ cells were seeded into 25-cm^2^ flasks with or without test agent(s) (B\[*a*\]P, PhIP, E~2~, or lindane) either individually or as a binary mixture, as indicated. Cells were incubated in 5% CO~2~ in air at 37°C in a humidified atmosphere for 24 hr. The medium was then replaced with fresh medium. Cells were cultured undisturbed for a further 7 days before removal of medium, washing with PBS and fixation with 70% EtOH. Colonies were then stained with 5% Giemsa and counted.

Immunohistochemical staining
----------------------------

Cells were disaggregated and resuspended in complete medium before seeding aliquots (5 mL; ∼ 1 × 10^5^ cells) into 60-mm petri dishes containing 24-mm glass coverslips. After allowing 24 hr for attachment, cells were treated for 24 hr with test agents, as indicated. Medium was then removed and the cells washed with PBS before immediate fixation with CytoFixx fixative (CellPath plc, Skelmersdale, UK). The following antisera in bovine serum albumin (0.2%) diluted with Tris-buffered saline (pH 7.6) (BSAT) were used: cyclin-dependent kinase inhibitor 1A (CDKN1A (P21^Waf1/Cip1^) mouse monoclonal (SX118, Isotype: IgG1) in a 1:20 dilution; Bcl-2 mouse monoclonal (124, Isotype: IgG1) in a 1:100 dilution and Bax rabbit polyclonal in a 1:50 dilution. Fixative was removed by soaking coverslips in 95% industrial methylated spirits (IMS) for 30 min. After a 5-min wash with tap water, coverslips were incubated in 1:5 normal goat sera in Tris-buffered saline (TBS) (0.05 M, pH 7.6) for 15 min in a humidified environment. After removal of excess sera, the cover-slips were incubated with primary antibody for 1 hr at room temperature. Using the StreptABComplex duet kit (DakoCytomation), coverslips were then washed for 5 min with TBS, incubated for 30 min with secondary anti-sera (goat anti-mouse/rabbit) in BSAT and washed again for 5 min with TBS. Then coverslips were incubated with tertiary anti-sera (avidinbiotin complex) in BSAT for 30 min and washed with TBS for 5 min. 3,3′-Diaminobenzidine (DAB) chromogen in Tris/HCl buffer (0.05 M, pH 7.6) with hydrogen peroxide (0.1%) was applied to preparations for 15 min followed by another 5-min tap water wash. Finally, slides were transferred to a rack and stained (1 min) with hematoxylin (50%), rinsed with tap water, blued in Scott's tap water for 15 sec and rinsed again. Preparations were stained for 1 min with eosin (0.1% in 0.1% calcium chloride), rinsed with tap water, and dehydrated with graded alcohol solutions through to xylene. Cell preparations were then mounted on microscope slides with Pertex mountant (CellPath plc, Newtown, UK). The percentage of positive cells was determined as the mean ± SD of five separate counts.

Quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR)
-------------------------------------------------------------------------------

Routinely cultured cells were disaggregated and resuspended in complete medium before seeding aliquots (5 mL; ∼ 1 × 10^5^ cells) into 60-mm petri dishes. After 24 hr, attached cells were treated for an additional 24 hr. Cells were then washed twice with PBS before lysis and total RNA extraction using the QIA-GEN RNeasy Kit in combination with the QIAGEN RNase free DNase kit (QIAGEN Ltd, Crawley, UK). DNase was incorporated into the extraction procedure to remove residual DNA, for example, pseudogene. RNA quality was routinely assessed in a 1.2% formaldehyde agarose gel; yield and purity were checked using a BioPhotometer (Eppendorf, Hamburg, Germany). RNA (0.4 μg) was reverse transcribed in a final volume of 20 μL containing Taqman reverse transcription reagents (Applied Biosystems, Warrington, UK): 1 × Taqman RT buffer; MgCl~2~ (5.5 mM); oligo d(T)~16~ (2.5 μM); dNTP mix (dGTP, dCTP, dATP, and dTTP; each at a concentration of 500 μM); RNase inhibitor (0.4 U/μL); reverse transcriptase (1.25 U/μL; Applied Biosystems, Warrington, UK); and RNase-free water. Reaction mixtures were then incubated at 25°C (10 min), 48°C (30 min), and 95°C (5 min).

cDNA samples were stored at --20°C before use. Primers ([Table 1](#t1-ehp0115s1-000129){ref-type="table"}) for *P21^WAF1/CIP1^*, *BCL-2*, *BAX*, *CYP1A1*, *CYP1A2*, *CYP1B1* and endogenous control or housekeeping gene cytoplasmic ACTB (β*-ACTIN*) were chosen using Primer Express software 2.0 (Applied Biosystems) and designed so that one primer spanned an exon boundary. Specificity was confirmed using the National Center for Biotechnology Information BLAST search tool (<http://www.ncbi.nlm.nih.gov/blast/index.shtml>). Quantitative real-time PCR was performed using an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Reaction mixtures contained 1 × SYBR Green PCR master mix (Applied Biosystems); forward and reverse primers (Invitrogen) at a concentration of 300 nM (*P21^WAF1/CIP1^*, *BCL-2*, *BAX*, *CYP1A1*, *CYP1A2*, *CYP1B1* or β*-ACTIN*); for *P21^WAF1/CIP1^*, *BCL-2*, *BAX*, *CYP1A1*, *CYP1A2*, or *CYP1B1* amplification 20 ng cDNA template cDNA template or for β*-ACTIN* amplification 5 ng cDNA template; made to a total volume of 25 μL with sterile H~2~O. Thermal cycling parameters included activation at 95°C (1 min) followed by 40 cycles each of denaturation at 95°C (15 sec) and annealing/extending at 60°C (1 min). Each reaction was performed in triplicate and "no-template" controls were included in each experiment. Dissociation curves were run to eliminate nonspecific amplification, including primer dimers.

Results
=======

[Table 2](#t2-ehp0115s1-000129){ref-type="table"} shows the micronucleus-forming activity of B\[*a*\]P, lindane, or a binary mixture of both test agents in MCF-7 cells. Dose-related increases in the number of MN and the TMN were observed following treatment with either B\[*a*\]P or lindane alone. Induction of MNi following B\[*a*\]P treatment at concentrations of 10^−7^ M, 10^−6^ M, or 10^−5^ M resulted in approximately 2-, 3-, and 5-fold increases in micronucleus-forming activity, respectively. Lindane-induced increases were also observed following treatment with 10^−12^ M (\~ 3-fold), 10^−11^ M (\~ 3-fold), or 10^−10^ M (\~ 4-fold). After treatment with a binary mixture, a marked elevation in micronucleus formation was induced compared with the effect of a single-agent exposure. In the presence of 10^−12^ M or 10^−11^ M lindane, clear dose-related increases in micronucleus formation were observed in the presence of B\[*a*\]P up to a concentration of 10^−6^ M; in combination with 10^−6^ M or 10^−5^ M B\[*a*\]P, these increases appeared to plateau ([Table 2](#t2-ehp0115s1-000129){ref-type="table"}; [Figure 1](#f1-ehp0115s1-000129){ref-type="fig"}). [Figure 1](#f1-ehp0115s1-000129){ref-type="fig"} shows that the micronucleus-forming effects of B\[*a*\]P treatment, in the absence or presence of 10^−12^ M lindane, were a consequence both of elevations in MN and TMN, namely, the summation of MNi in binucleate cells. In combination with 10^−10^ M lindane, dose-related increases in micronucleus formation in the presence of all B\[*a*\]P concentrations tested occurred; in the presence of 10^−5^ M B\[*a*\]P, approximately 10-fold increases in MNi compared with background control levels were observed ([Table 2](#t2-ehp0115s1-000129){ref-type="table"}). Of note was the observation that micronucleus formation following treatment with 10^−11^ M lindane, in the absence or presence of B\[*a*\]P, was less than that observed with corresponding 10^−12^ M--induced effects; however, further increases in induced MNi were observed at the higher 10^−10^ M concentration ([Table 2](#t2-ehp0115s1-000129){ref-type="table"}).

The effects of lindane on mitotic rate (percentage of binucleate cells) and clonogenic survival (percentage of plating efficiency) in B\[*a*\]P-treated cells are shown in [Figure 2A,B](#f2-ehp0115s1-000129){ref-type="fig"}. Treatment for 24 hr with B\[*a*\]P, in the absence of lindane, resulted in dose-related reductions in the percentage of binucleate cells from a background control level of 12.2% ± 0.7 to 6.6% ± 0.5 (10^−5^ M) ([Figure 2A](#f2-ehp0115s1-000129){ref-type="fig"}). In the presence of 10^−12^ M, 10^−11^ M, or 10^−10^ M lindane, concentration-dependent reductions in mitotic rate of approximately 20, 30, and 45%, respectively, were observed with or without B\[*a*\]P. Seven-day incubation, subsequent to a 24-hr treatment, resulted in B\[*a*\]P-induced reductions in the percentage of plating efficiency from a background control level of 35.4% ± 3.5 to 32.8% ± 4.7 (10^−8^ M), 28.1% ± 6.4 (10^−7^ M), 14.9% ± 4.2 (10^−6^ M), and 0 (10^−5^ M) ([Figure 2B](#f2-ehp0115s1-000129){ref-type="fig"}). Lindane, at the concentrations employed in this study, was not found to markedly alter clonogenic survival of MCF-7 cells in the absence or presence of B\[*a*\]P ([Figure 2B](#f2-ehp0115s1-000129){ref-type="fig"}).

[Figure 3](#f3-ehp0115s1-000129){ref-type="fig"} shows the micronucleus-forming activities, in MCF-7 cells of 24-hr treatments with PhIP (0.5 μM), lindane (10^−12^ M) or a binary mixture of both test agents. Both agents individually induced 2- to 4-fold increases in MNi. However, treatment with a binary mixture resulted in levels of MN and TMN of 87 and 130 (a 5- to 8-fold increase) compared with a background control level of 15 and 16, respectively ([Figure 3](#f3-ehp0115s1-000129){ref-type="fig"}).

The effects of E~2~ (10^−9^ M), lindane (10^−12^ M) or of a binary mixture of both test agents on the immunocytochemical detection of p53, p21^Waf1/Cip1^, Bcl-2, and Bax proteins after 24-hr treatment are shown in [Figure 4](#f4-ehp0115s1-000129){ref-type="fig"}. E~2~ induced a modest increase in p53- and p21^Waf1/Cip1^-positive MCF-7 cells (17.8% ± 3.3 and 13.2% ± 1.5 compared with background control levels of 8.4% ± 1.5 and 8.2% ± 2.8, respectively). Lindane appeared to reduce levels of p21^Waf1/Cip1^-positive cells both in the absence (7.2% ± 1.5) or presence (5.6% ± 1.5) of E~2~. However, marked increases in Bcl-2--positive cells were induced by either E~2~ or lindane; the binary mixture elevated the percentage of both Bcl-2-- and Bax-positive cells ([Figure 4](#f4-ehp0115s1-000129){ref-type="fig"}). From background control levels of 33.8% ± 3.1 (Bcl-2--positive) and 12.8% ± 1.9 (Bax-positive) cells, E~2~, or lindane treatment gave rise to percentages of cells staining positive for Bcl-2 of 58.8% ± 6.5 or 67.0% ± 4.3 and for Bax of 9.8% ± 2.8 or 6.4% ± 2.3, respectively. A binary mixture gave rise to levels of 74.6% ± 5.6 Bcl-2--positive cells and 55.0% ± 4.5 Bax-positive cells ([Figure 4](#f4-ehp0115s1-000129){ref-type="fig"}).

The effects of different treatments on the quantitative expression of six genes (*P21^WAF1/CIP1^*, *BCL-2*, *BAX*, *CYP1A1*, *CYP1A2*, and *CYP1B1*) were examined. To assess background fluctuation, we examined the variability in gene expression within control cell cultures (*n* = 6). Taking one control as the calibrator, marked intraexperimental variability was observed for relative levels of quantitative expression of *CYP1A1* (0.7--1.5), *CYP1A2* (0.5--1.7), and *CYP1B1* (0.6--1.5). In contrast, calibrator-controlled quantitative expression levels for *P21^WAF1/CIP1^* (1.1--1.4), *BCL-2* (0.9--1.0), or *BAX* (0.9--1.3) appeared to be less variable.

In a panel of experiments (listed 1--5), the effects of a genotoxin (B\[*a*\]P or PhIP) in the absence or presence of 10^−9^ M E~2~ or 10^−11^ M lindane, on the quantitative gene expression of *P21^WAF1/CIP1^*, *BCL-2*, or *BAX* were examined ([Table 3](#t3-ehp0115s1-000129){ref-type="table"}). Although 24-hr treatment with E~2~ or lindane (with or without 10^−8^ M B\[*a*\]P or 0.5 μM PhIP) was associated with a reduction in *P21^WAF1/CIP1^* expression in experiments 1, 3, and 5, this was not apparent in experiments 2 and 4. In contrast, 24-hr treatment with 10^−6^ M B\[*a*\]P resulted in 36.1- and 56.3-fold elevations in *P21^WAF1/CIP1^* expression in experiments 2 and 4, respectively; in the presence of E~2~ or lindane, small reductions in these increases in gene expression were observed ([Table 3](#t3-ehp0115s1-000129){ref-type="table"}). No marked alterations in *BCL-2* or *BAX* expression were observed following 24-hr treatment with 10^−9^ M E~2~ or 10^−11^ M lindane. However, 10^−6^ M B\[*a*\]P was observed to reduce the ratio of *BCL-2:BAX* expression to approximately 0.1 as observed in experiments 2 and 4; effects that were not markedly altered in the presence of a binary mixture ([Table 3](#t3-ehp0115s1-000129){ref-type="table"}).

[Figure 5A](#f5-ehp0115s1-000129){ref-type="fig"},B shows the effects of 24-hr treatment with B\[*a*\]P (10^−8^ M or 10^−6^ M), in the absence or presence of E~2~ (10^−10^ M or 10^−9^ M), on the immunocytochemical detection of p53, p21^Waf1/Cip1^, Bcl-2, and Bax proteins in MCF-7 cells. Although treatment with B\[*a*\]P was associated with dose-related increases in the percentage of p53- and p21^Waf1/Cip1^-positive cells, no such E~2~-induced alterations were observed. However, marked E~2~-induced alterations in the percentages of Bcl-2-- and Bax-positive cells were observed. Treatment with 10^−8^ M B\[*a*\]P or 10^−10^ M E~2~ resulted in marked elevations in the percentage of Bcl-2--positive cells (52.4% ± 4.7 and 72.0% ± 4.0, respectively, compared with a background control level of 31.2% ± 3.7); E~2~ also reduced the percentage of Bax-positive cells from a background control level of 23.2% ± 4.1 to 6.2% ± 1.5 ([Figure 5A](#f5-ehp0115s1-000129){ref-type="fig"}). Similar modulations in the levels of Bcl-2--(47.8% ± 7.9) and Bax-positive (7.4% ± 3.0) cells were apparent after exposure to a binary mixture. The resulting ratios of Bcl-2--positive: Bax-positive cells were 1.3, 1.8, 11.6, and 6.5 in control, B\[*a*\]P-treated, E~2~-treated and binary mixture--treated cells, respectively ([Figure 5A](#f5-ehp0115s1-000129){ref-type="fig"}). In contrast, the ratio of Bcl-2--positive: Bax-positive cells following 24-hr treatment with 10^−6^ M B\[*a*\]P (58.0% ± 3.0 and 82.2% ± 1.9 Bcl-2-- and Bax-positive cells, respectively) was observed to be 0.7 compared with a background control level of 2.4 (37.8% ± 5.1 and 16.0% ± 2.3 Bcl-2--and Bax-positive cells, respectively) ([Figure 5B](#f5-ehp0115s1-000129){ref-type="fig"}). The ratio of Bcl-2-- positive: Bax-positive cells was again markedly elevated (8.4; from 78.6% ± 5.8 and 9.4% ± 2.1 Bcl-2-- and Bax-positive cells, respectively) following 24-hr treatment with 10^−9^ M E~2~, whereas with a binary mixture (E~2~ plus B\[*a*\]P), a ratio of 0.9 (82.2% ± 2.8 and 87.0% ± 2.9 Bcl-2-- and Bax-positive cells, respectively) was observed ([Figure 5A](#f5-ehp0115s1-000129){ref-type="fig"}).

Treatment with 0.5 μM PhIP and/or 10^−9^ M E~2~ did not result in marked alterations in the levels of p53- or p21^Waf1/Cip1^-positive MCF-7 cells ([Figure 6](#f6-ehp0115s1-000129){ref-type="fig"}). However, both agents induced marked modulations in the levels of Bcl-2-- and Bax-positive cells when tested either individually or in a binary mixture. Treatment with PhIP or E~2~ elevated the percentage of Bcl-2--positive cells (73.0% ± 22.0 and 78.6% ± 4.0, respectively, compared with a background control level of 14.2% ± 4.9); PhIP also increased the percentage of Bax-positive cells from a background control level of 3.4% ± 1.7 to 22.0% ± 4.8. Exposure of MCF-7 cells to a binary mixture (0.5 μM PhIP plus 10^−9^ M E~2~) resulted in increases in both Bcl-2-- (55.0% ± 3.9) and Bax-positive (54.0% ± 4.6) MCF-7 cells. The resulting ratios of Bcl-2--positive:Bax-positive cells were 4.2, 3.3, 19.7, and 1.0 in control, PhIP-treated, E~2~-treated, and binary mixture--treated cells, respectively ([Figure 6](#f6-ehp0115s1-000129){ref-type="fig"}).

Treatment with 10^−8^ M B\[*a*\]P, 10^−12^ M lindane, or 0.5 μM PhIP was not observed to alter levels of p53- or p21^Waf1/Cip1^-positive cells; however, a binary mixture of lindane plus PhIP induced marked increases in p53- (41.4% ± 5.0) and p21^Waf1/Cip1^-positive (33.0% ± 4.4) cells compared with background control levels of 20.0% ± 1.9 and 20.2% ± 2.6, respectively ([Figure 7A,B](#f7-ehp0115s1-000129){ref-type="fig"}). Despite these observations, the low-dose treatments employed markedly altered levels of Bcl-2-- and Bax-positive cells. B\[*a*\]P increased the levels of both Bcl-2-- (37.6% ± 3.6) and Bax-positive (13.8% ± 3.5) cells giving rise to a ratio of 2.7 compared with a background control ratio of 7.5 (16.6% ± 2.7 and 2.2% ± 1.3 Bcl-2-- and Bax-positive cells, respectively) ([Figure 7A](#f7-ehp0115s1-000129){ref-type="fig"}). In contrast, lindane-induced alterations in the ratio of Bcl-2--positive: Bax-positive cells were 13.4 (37.4% ± 2.9 and 2.8% ± 1.3 Bcl-2-- and Bax-positive cells, respectively) ([Figure 7A](#f7-ehp0115s1-000129){ref-type="fig"}) and 6.1 (65.8% ± 2.8 and 10.8% ± 3.6 Bcl-2-- and Bax-positive cells, respectively) ([Figure 7B](#f7-ehp0115s1-000129){ref-type="fig"}). The background control ratio of Bcl-2--positive: Bax-positive cells was 4.7 (40.8% ± 4.0 and 8.6% ± 1.8 Bcl-2-- and Bax-positive cells, respectively) in [Figure 7B](#f7-ehp0115s1-000129){ref-type="fig"}. Exposure to a binary mixture resulted in ratios of Bcl-2--positive: Bax-positive cells of 4.2 (39.6% ± 3.8 and 9.4% ± 3.7 Bcl-2-- and Bax-positive cells, respectively) ([Figure 7A](#f7-ehp0115s1-000129){ref-type="fig"}) and 0.6 (56.0% ± 4.9 and 89.6% ± 0.9 Bcl-2-- and Bax-positive cells, respectively) ([Figure 7B](#f7-ehp0115s1-000129){ref-type="fig"}).

[Table 4](#t4-ehp0115s1-000129){ref-type="table"} shows the results of a panel of experiments (listed 1--4) examining the effects of B\[*a*\]P (10^−8^ M or 10^−6^ M), E~2~ (10^−10^ M or 10^−9^ M), lindane (10^−12^ M, 10^−11^ M or 10^−9^ M), and various binary mixtures on the quantitative gene expression of *CYP1A1*, *CYP1A2* or *CYP1B1*. Interexperimental variations in the ability of low-dose treatments to alter *CYP* expression were observed; in experiment 1, 10^−8^ M B\[*a*\]P and/or 10^−9^ M E~2~ did not induce the *CYP* isoenzymes examined, whereas in experiment 4, 3- to 4-fold increases in the *CYP1A1* expression were observed. Similarly, lindane-associated inter-experimental variation was noted; in experiment 3, 10^−11^ M lindane treatment was associated with reductions in *CYP* expression, whereas in experiment 4, 24-hr treatment with either 10^−12^ M or 10^−9^ M lindane induced a 2- to 4-fold increase in *CYP1A1*. Treatment with 10^−6^ M B\[*a*\]P consistently induced marked elevations in *CYP1A1*, *CYP1A2*, and *CYP1B1* expression in MCF-7 cells ([Table 4](#t4-ehp0115s1-000129){ref-type="table"}).

Discussion
==========

Humans may be exposed to different combinations of exogenous factors, including xenobiotics; evaluating only the toxicity of individual exposures might underestimate mixture effects ([@b6-ehp0115s1-000129]; [@b24-ehp0115s1-000129]; [@b25-ehp0115s1-000129]; [@b27-ehp0115s1-000129]). Apparently innocuous components of a mixture may significantly modulate underlying susceptibility of target cells to more toxic constituents ([@b40-ehp0115s1-000129]). Modulating effects may occur through ligand-activated, receptor-mediated mechanisms ([@b9-ehp0115s1-000129]) or interference with cell cycle control ([@b30-ehp0115s1-000129]). Some xenobiotics may not only induce DNA damage but also may drive clonal expansion, often at low-dose levels not dissimilar to typical human exposures; such effects may explain the target-organ specificity of some procarcinogens ([@b22-ehp0115s1-000129]; [@b32-ehp0115s1-000129]). Endocrine-active properties of xenobiotics may play a role in the etiology of much human pathology ([@b37-ehp0115s1-000129]) in hormone-responsive tissues ([@b34-ehp0115s1-000129]).

B\[*a*\]P, PhIP, or lindane individually induced 2- to 5-fold increases in MNi; treatment with a binary mixture gave rise to approximately 10-fold increases ([Table 2](#t2-ehp0115s1-000129){ref-type="table"}, [Figures 1](#f1-ehp0115s1-000129){ref-type="fig"} and [3](#f3-ehp0115s1-000129){ref-type="fig"}). Consistent with previous findings ([@b18-ehp0115s1-000129]) that lindane (γ-HCH) induces a cell cycle arrest in MCF-7 cells, dose-related reductions in mitotic rate were observed following treatment with this agent ([Figure 2A](#f2-ehp0115s1-000129){ref-type="fig"}). However, in a binary mixture lindane was not observed to alter B\[*a*\]P-induced reductions in clonogenic survival ([Figure 2B](#f2-ehp0115s1-000129){ref-type="fig"}). At micromolar concentrations, B\[*a*\]P markedly altered gene expression by inducing up-regulation of *P21^WAF1/CIP1^* and *CYP* isoenzymes and down-regulation of *BCL-2* ([Tables 4](#t4-ehp0115s1-000129){ref-type="table"} and 5). However, with 24-hr treatment, no marked modulations in gene expression were apparent following low-dose treatments (less than or equal to nanomolar range) with either individual-agent or binary-mixture treatments ([Tables 4](#t4-ehp0115s1-000129){ref-type="table"} and 5). This was despite observations that 10^−9^ M E~2~ or lindane did induce a 3-fold elevation in *CYP1A1* expression in one experiment ([Table 4](#t4-ehp0115s1-000129){ref-type="table"}). Such observations suggest that modulations in expression of the candidate genes examined may be transient following low-dose treatment or that other factors are responsible for the effects observed, for example, oxidative damage ([@b15-ehp0115s1-000129]; [@b35-ehp0115s1-000129]).

Pleiotropic induction of unrelated phenotypic effects appears to be a feature of oestrogens, endocrine disruptors and PAHs ([@b14-ehp0115s1-000129]; [@b28-ehp0115s1-000129]; [@b29-ehp0115s1-000129]). Endogenous hormones facilitate cell growth/proliferation, differentiation, behavior, and activity in many tissues. In responsive cells, stimulatory effects are observable at less than or equal to nanomolar concentrations ([@b46-ehp0115s1-000129]). Different xenobiotics may also induce effects through receptor-mediated processes ([@b18-ehp0115s1-000129]; [@b22-ehp0115s1-000129]), for example, E~2~ appears to increase the percentage of Bcl-2--positive cells ([Figures 4](#f4-ehp0115s1-000129){ref-type="fig"}--[6](#f6-ehp0115s1-000129){ref-type="fig"}). A binary mixture of E~2~ and lindane induced a marked reduction in the ratio of Bcl-2--positive to Bax-positive cells ([Figure 4](#f4-ehp0115s1-000129){ref-type="fig"}); this was due to an apparently induced increase in Bax-positive cells while the percentage of Bcl-2--positive cells remained unchanged. 2,3,7,8-Tetra-chlorodibenzo-*p*-dioxin is cytostatic in MCF-7 cells through an ability to function as an antiestrogen and down-regulate a battery of E~2~-induced proliferative responses ([@b8-ehp0115s1-000129]; [@b44-ehp0115s1-000129]); whether lindane may induce a similar effect through a reduction in Bcl-2:Bax ratio remains to be determined.

In a dose-related fashion, B\[*a*\]P elevated the percentage of p53-positive cells ([@b21-ehp0115s1-000129]) and the downstream cyclin-dependent kinase inhibitor, p21^Waf1/Cip1^ ([Figure 5](#f5-ehp0115s1-000129){ref-type="fig"}). PhIP (0.5 μM) apparently failed to increase the percentage of p53-positive or p21^Waf1/Cip1^-positive MCF-7 cells ([Figures 6](#f6-ehp0115s1-000129){ref-type="fig"} and [7](#f7-ehp0115s1-000129){ref-type="fig"}); at higher concentrations and after metabolic activation, PhIP has been shown to elevate these intracellular factors in MCF10A cells ([@b4-ehp0115s1-000129]). However, PhIP markedly elevated the percentage of Bcl-2--positive cells while the levels of Bax-positive cells remained relatively low; although B\[*a*\]P also increased levels of Bcl-2--positive cells, marked increases in Bax-positive cells were also apparent ([Figures 5](#f5-ehp0115s1-000129){ref-type="fig"}--[7](#f7-ehp0115s1-000129){ref-type="fig"}). In a binary mixture with E~2~ or lindane, a reversal in B\[*a*\]P-induced reductions in the ratio of Bcl-2--positive to Bax-positive cells was observed ([Figures 5](#f5-ehp0115s1-000129){ref-type="fig"} and [7](#f7-ehp0115s1-000129){ref-type="fig"}). However, E~2~ or lindane in combination with PhIP appeared to reverse potential hormone-driven survival characteristics observed as marked reductions in the ratio of Bcl-2--positive to Bax-positive cells ([Figures 6](#f6-ehp0115s1-000129){ref-type="fig"} and [7](#f7-ehp0115s1-000129){ref-type="fig"}).

In this study we investigated whether binary mixtures of DNA-reactive procarcino-gens and hormonelike compounds at environmentally relevant low-dose concentrations give rise to markedly elevated DNA damage in target cells while also modulating survival. Our results suggest that this might indeed be the case.

This article is part of the monograph "Endocrine Disruptors---Exposure Assessment, Novel End Points, and Low-Dose and Mixture Effects."
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![Micronucleus-forming activity of B\[*a*\]P with (*A,C,E*) or without lindane (*B,D,F*). Cell suspensions (3 mL, 1 × 10^4^ cells) in 30-mm petri dishes were prepared and treated in the CBMN assay as described in "Materials and Methods." Micronucleus formation was scored in 1,000 binucleate cells. (*E,F*) Number of MNi in binucleate MCF-7 cells were scored from 1 to 5, with 5 representing the maximum score for this study.](ehp0115s1-000129f1){#f1-ehp0115s1-000129}

![Effects of B\[*a*\]P, with or without lindane, on mitotic rate (*A*) and percentage of plating efficiency (*B*) in MCF-7 cells. After 24-hr treatment, cells were either blocked at cytokinesis before subsequent staining or cultured undisturbed for a further 7 days as described in "Materials and Methods." Mitotic rate was estimated as percentage of binucleate cells from the mean ± SD of three separate counts (*n* = 500 cells). Clonogenic survival was calculated by estimating the percentage of colonies counted over the number of cells initially seeded.](ehp0115s1-000129f2){#f2-ehp0115s1-000129}

![Micronucleus-forming activity of PhIP with or without lindane. Cell suspensions (3 mL, \~ 1 × 10^4^ cells) in 30-mm petri dishes were prepared and treated in the CBMN assay as described in "Materials and Methods." Micronucleus formation was scored in 1,000 binucleate cells. (*C*) Number of MNi in binucleate MCF-7 cells were scored from 1 to 5, with 5 representing the maximum score for this study.](ehp0115s1-000129f3){#f3-ehp0115s1-000129}

![Immunocytochemical analysis of MCF-7 breast cells treated with E~2~ and/or lindane. Cells were treated as indicated for 24 hr on coverslips, after which they were analyzed for protein expression as described in "Materials and Methods." The percentages of cells staining positive were determined after five separate counts of 100 cells and are presented as mean ± SD.](ehp0115s1-000129f4){#f4-ehp0115s1-000129}

![Immunocytochemical analysis of MCF-7 breast cells treated with B\[*a*\]P with or without E~2~. Cells were treated with 10^−8^ M B\[*a*\]P and/or 10^−10^ M E~2~ (*A*) or 10^−6^ M B\[*a*\]P and/or 10^−9^ M E~2~ (*B*) for 24 hr on cover-slips, after which they were analyzed for protein expression as described in "Materials and Methods." The percentages of cells staining positive were determined after five separate counts of 100 cells and are presented as mean ± SD.](ehp0115s1-000129f5){#f5-ehp0115s1-000129}

![Immunocytochemical analysis of MCF-7 breast cells treated with PhIP and/or E~2~. Cells were treated as indicated for 24 hr on coverslips, after which they were analyzed for protein expression as described in "Materials and Methods." The percentages of cells staining positive were determined after five separate counts of 100 cells and are presented as mean ± SD.](ehp0115s1-000129f6){#f6-ehp0115s1-000129}

![Immunocytochemical analysis of MCF-7 breast cells treated with (*A*) B\[*a*\]P and/or lindane or (*B*) PhIP and/or lindane. Cells were treated as indicated for 24 hr on coverslips, after which they were analyzed for protein expression as described in "Materials and Methods." The percentages of cells staining positive were determined after five separate counts of 100 cells and are presented as the mean ± SD.](ehp0115s1-000129f7){#f7-ehp0115s1-000129}

###### 

Primers used for quantitative real-time RT-PCR analyses.

  -----------------------------------------------------------------------------------------------------
  GenBank accession no.   Gene symbol        Primer                Sequence (5′→3′)
  ----------------------- ------------------ --------------------- ------------------------------------
  NM_078467               *P21^WAF1/CIP1^*   *P21^WAF1/CIP1^*-F\   GAC CAG CAT GAC AGA TTT CTA CCA\
                                             *P21^WAF1/CIP1^*-R    TTC CTG TGG GCG GAT TAG G

  NM_000633               *BCL-2*            *BCL-2*-F\            GGC TGG GAT GCC TTT GTG\
                                             *BCL-2*-R             GCC AAA CTG AGC AGA GTC TTC AG

  AF007826                *BAX*              *BAX*-F\              CCT GGG TTC AAG CGA TTC AC\
                                             *BAX*-R               GTG CAC AGG GCC TGT AAT CC

  BC023019                *CYP1A1*           *CYP1A1*-F\           ACT TCA TCC CTA TTC TTC GCT ACC T\
                                             *CYP1A1*-R            CGG ATG TGG CCC TTC TCA

  NM_000761               *CYP1A2*           *CYP1A2*-F\           GAC ATC TTT GGA GCA GGA TTT GA\
                                             *CYP1A2*-R            CTT CCT CTG TAT CTC AGG CTT GGT

  NM_000104               *CYP1B1*           *CYP1B1*-F\           GTA CCG GCC ACT ATC ACT GAC A\
                                             *CYP1B1*-R            CAC ATC AGG ATA CCT GGT GAA GAG

  AK222925                β*-ACTIN*          β*-ACTIN*-F\          CCT GGC ACC CAG CAC AAT\
                                             β*-ACTIN*-R           GCC GAT CCA CAC GGA GTA CT
  -----------------------------------------------------------------------------------------------------

Abbreviations: F, forward primer; R, reverse primer. Nucleotide sequences were obtained from [@b11-ehp0115s1-000129].

###### 

Micronucleus formation in MCF-7 cells treated with B\[*a*\]P and/or lindane.

                           Lindane (γ-HCH) (M)         
  ------------ ----- ----- --------------------- ----- -----
  Background   MN    21    67                    64    78
               TMN   24    86                    90    108
  10^−8^       MN    28    86                    77    123
               TMN   33    118                   103   186
  10^−7^       MN    45    120                   115   159
               TMN   56    193                   177   244
  10^−6^       MN    91    167                   135   139
               TMN   138   293                   217   252
  10^−5^       MN    110   170                   132   200
               TMN   183   273                   198   330

Abbreviations: MN, the number of micronucleated binucleate cells scored per treatment; TMN, the total number of micronuclei scored per treatment. MCF-7 cells were treated for 24 hr in the presence or absence of test agents, as indicated, before cytokinesis block with cytochalasin-B. After further 24-hr incubation, cells were fixed and stained with 5% Giemsa as described in "Materials and Methods."

###### 

Relative gene expression measured by quantitative real-time RT-PCR.

                                      Relative expression levels in MCF-7 cells               
  ----------------------------------- ------------------------------------------- ----------- -----------
  Experiment 1 (mean ± SD, *n* = 5)                                                           
   Control                            1 (c)                                       1 (c)       1 (c)
   10^−8^ M B\[*a*\]P                 1.2 ± 0.4                                   0.9 ± 0.3   1.1 ± 0.2
   10^−9^ M E~2~                      0.6 ± 0.1                                   0.9 ± 0.3   1.2 ± 0.2
   Binary mixture                     0.9 ± 0.2                                   0.9 ± 0.3   0.6 ± 0.6
  Experiment 2                                                                                
   Control                            1 (c)                                       1 (c)       1 (c)
   10^−6^ M B\[*a*\]P                 36.1                                        0.2         1.5
   10^−9^ M E~2~                      1.0                                         1.3         1.3
   Binary mixture                     35.5                                        0.1         1.4
  Experiment 3                                                                                
   Control                            1 (c)                                       1 (c)       1 (c)
   10^−8^ M B\[*a*\]P                 1.1                                         1.3         1.0
   10^−11^ M lindane                  0.7                                         1.2         1.0
   Binary mixture                     0.9                                         1.0         1.0
  Experiment 4                                                                                
   Control                            1 (c)                                       1 (c)       1 (c)
   10^−6^ M B\[*a*\]P                 56.3                                        0.3         2.1
   10^−11^ M lindane                  1.9                                         2.0         2.9
   Binary mixture                     47.9                                        0.3         2.2
  Experiment 5                                                                                
   Control                            1 (c)                                       1 (c)       1 (c)
   0.5 μM PhIP                        1.4                                         1.2         1.4
   10^−9^ M E~2~                      0.8                                         1.0         1.6
   Binary mixture                     0.6                                         0.7         1.1

calibrator, which for the purposes of these experiments were untreated controls. Relative gene expression levels following 24-hr treatment in the presence or absence of test agents, as indicated. Reverse transcription of total RNA and subsequent amplification was carried out using primers as described in "Materials and Methods." Within each experiment, reactions were performed in triplicate and "no-template" controls were included. Averaged threshold cycle (C~T~) values for each reaction were normalized to β*-ACTIN* values thus giving ΔC~T~ values. Alterations in gene expression were determined by comparing treatment groups with the calibrator, giving ΔΔC~T~ values. Finally, relative gene expression was calculated using the formula 2^−ΔΔC~T~^.

###### 

Relative gene expression measured by quantitative real-time RT-PCR.

                        Relative expression levels in MCF-7 cells           
  --------------------- ------------------------------------------- ------- -------
  Experiment 1                                                              
   Control              1 (c)                                       1 (c)   1 (c)
   10^−8^ M B\[*a*\]P   0.8                                         1.0     0.9
   10^−9^ M E~2~        0.7                                         0.8     1.5
   Binary mixture       0.9                                         0.5     1.8
  Experiment 2                                                              
   Control              1 (c)                                       1 (c)   1 (c)
   10^−10^ M E~2~       1.4                                         0.3     0.9
   10^−8^ M B\[*a*\]P   1.6                                         1.2     1.4
   Binary mixture1      2.5                                         1.0     1.8
   10^−6^ M B\[*a*\]P   462.7                                       5.6     28.6
   Binary mixture 2     430.5                                       3.7     26.5
  Experiment 3                                                              
   Control              1 (c)                                       1 (c)   1 (c)
   10^−6^ M B\[*a*\]P   370.9                                       15.4    41.6
   10^−11^ M lindane    0.6                                         0.4     0.6
   Binary mixture       183.9                                       12.0    23.3
  Experiment 4                                                              
   Control              1 (c)                                       1 (c)   1 (c)
   10^−9^ M E~2~        3.6                                         0.9     1.6
   10^−8^ M B\[*a*\]P   3.6                                         1.4     1.3
   10^−6^ M B\[*a*\]P   457.7                                       9.4     23.9
   10^−12^ M lindane    2.0                                         0.8     1.0
   10^−9^ M lindane     3.6                                         1.3     1.4

calibrator, which for the purposes of these experiments were untreated controls. Where indicated binary mixture 1 = 10^−10^ M E~2~ + 10^−8^ M B\[*a*\]P; binary mixture 2 = 10^−10^ M E~2~ + 10^−6^ M B\[*a*\]P. Relative gene expression levels after 24-hr treatment in the presence or absence of test agents, as indicated. Reverse transcription of total RNA and subsequent amplification was carried out using primers as described in "Materials and Methods." Within each experiment, reactions were performed in triplicate and "no-template" controls were included. Averaged threshold cycle (C~T~) values for each reaction were normalized to β*-ACTIN* values, thus giving ΔC~T~ values. Alterations in gene expression were determined by comparing treatment groups with the calibrator, giving ΔΔC~T~ values. Finally, relative gene expression was calculated using the formula 2^−ΔΔC~T~^.
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